Saturday 17 October 2026
Export ALLR’s income statement to Excel — free account
Allarity Therapeutics, Inc.
ALLR Healthcare Biotechnology
Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00. In the quarter to June 2026, EPS fell 40.0%, free cash flow grew 53.2% and total debt rose 3.56%, each against the same quarter a year earlier.
0.90
0.07
+8.43%
Follow ALLR
Allarity Therapeutics, Inc. (ALLR) P/E ratio
Allarity Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (January 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
74
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ICU SeaStar Medical Holding Corporation compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| RVLP RVL Pharmaceuticals PLC compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| HIND Vyome Holdings, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)